What does Teva's generic Narcan commitment involve?
As part of its opioid settlement, Teva agreed to supply up to $1.2 billion of generic naloxone nasal spray over ten years — or states could elect $240 million in cash instead, at 20% of the wholesale value.
As part of its opioid settlement, Teva agreed to supply up to $1.2 billion of its generic version of Narcan, the naloxone nasal spray used to reverse opioid overdoses, valued at wholesale acquisition cost, over ten years. States could instead elect to receive cash at 20% of the wholesale value, or $240 million in total, in lieu of product.
Supporters said the naloxone provision would put a life-saving medicine into communities. Teva also reached a separate settlement with Nevada for $193 million over 20 years, resolving the case before a scheduled trial, and a settlement with Native American tribes with 100% participation. The overall deal covers all 50 states and more than 99% of litigating local governments.